WE believe
portfolio
alpha
TEAM
IMPACT
Impact Report 2025
Impact Report 2024
Impact Report 2023
Impact Report 2022
Impact Report 2021
news & INSIGHTS
Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy